Skip to content

Apogee Therapeutics, Inc. APGE Change in Other Assets

Change in Other Assets at other companies

Eli Lilly logo
Eli LillyLLY
$1.65B+98.4%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$1.03M-27.7%
Arrowhead Research logo
Arrowhead ResearchARWR
$13.18M+2,127%
IQVIA logo
IQVIAIQV
-$54.5M-3,014%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX

Other financials

Income statement

See full
Operating income-$82.8M-31.2%
Net income-$74.1M-33.9%
EPS (diluted)-$1.06-11.6%

Balance sheet

See full
Cash & equivalents$451.8M+323%
Total debt$8.0M-31.9%
Total assets$1.3B+81.1%

Cash flow

See full
Operating cash flow-$55.6M-14.6%
CapEx$62.0K
Free cash flow-$62.8M+7.3%

Valuation

See full
Market cap$6.81B+189%
Enterprise value$6.37B+181%

Returns & leverage

See full
Current ratio32.6×+16.8×

Where this comes from

Reported directly by Apogee Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentAssets.

The official record: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Apogee Therapeutics, Inc.'s change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Apogee Therapeutics, Inc.'s change in other assets?
Apogee Therapeutics, Inc. (APGE) reported change in other assets of -$155K in Q1 2026.
How has Apogee Therapeutics, Inc.'s change in other assets changed year-over-year?
Apogee Therapeutics, Inc.'s change in other assets decreased by 102.3% year-over-year, from $6.84M to -$155K.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.